MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience
Background. The MammaPrint (MP) diagnostic assay stratifies breast cancer patients into high- and low-risk groups using mRNA analysis of a 70-gene profile. The assay is validated for assessment of patients with estrogen receptor positive or negative tumors less than 5 cm with 3 or fewer malignant ly...
Main Authors: | C. Francisco Espinel, Shaughn Keating, Hanina Hibshoosh, Bret Taback, Kathie-Ann Joseph, Mahmoud El-Tamer, Sheldon Feldman |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Scientifica |
Online Access: | http://dx.doi.org/10.6064/2012/942507 |
Similar Items
-
Prognostic Value of MammaPrint in Invasive Lobular Breast Cancer
by: Inès J. Beumer, et al.
Published: (2016-01-01) -
Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer
by: Inès J. Beumer, et al.
Published: (2016-12-01) -
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
by: Hatem Soliman, et al.
Published: (2020-01-01) -
MammaPrint risk score distribution in breast cancer patients with BRCA1/2 mutations
by: Mampunye, Lwando
Published: (2020) -
Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens
by: M. Kleijn, et al.
Published: (2021-04-01)